Comparison of Bleeding Risk Between Colistin–Tigecycline and Colistin–Carbapenem Treatment Regimens: A Retrospective Cohort Study

References

• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. doi:10.1093/cid/ciaa147833106864
   PubMed Web of Science ®Google Scholar
• Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microb Infect. 2019;8(1):1747–1759. doi:10.1080/22221751.2019.1698273
   PubMedGoogle Scholar
• Acar A, Karaahmetoğlu G, Akalın H, Altay AF. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Glob Antimicrob Res. 2019;18:64–70. doi:10.1016/j.jgar.2019.01.032
   PubMed Web of Science ®Google Scholar
• van Loon K, Voor I, ‘t Holt AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:e01730–17.29038269
   PubMed Web of Science ®Google Scholar
• Teerawattanapong N, Panich P, Kulpokin D, et al. A systematic review of the burden of multidrug-resistant healthcare-associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2018;39(5):525–533. doi:10.1017/ice.2018.5829580299
   PubMed Web of Science ®Google Scholar
• Scudeller L, Righi E, Chiamenti M, et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int J Antimicrob Agents. 2021;57(5):106344. doi:10.1016/j.ijantimicag.2021.10634433857539
   PubMed Web of Science ®Google Scholar
• Abdul-Mutakabbir JC, Yim J, Nguyen L, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii. Antibiotics. 2021;10(7). doi:10.3390/antibiotics10070880.
   Web of Science ®Google Scholar
• Zhou YF, Liu P, Zhang CJ, Liao XP, Sun J, Liu YH. Colistin combined with tigecycline: a promising alternative strategy to combat Escherichia coli harboring bla NDM- 5 and mcr-1. Front Microbiol. 2019;10:2957. doi:10.3389/fmicb.2019.0295731969868
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang J, Fu Y, et al. Synergetic effects of combined treatment of colistin with meropenem or amikacin on Carbapenem-Resistant Klebsiella pneumoniae in vitro. Front Cell Infect Microbiol. 2019;9:422. doi:10.3389/fcimb.2019.0042231921701
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Athanassaki F, Pitiriga V, Falagas ME. Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: a systematic review. J Glob Antimicrob Resist. 2019;17:250–259. doi:10.1016/j.jgar.2019.01.00430658202
   PubMed Web of Science ®Google Scholar
• Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent). 2006;19(2):155–161. doi:10.1080/08998280.2006.1192815416609746
   PubMedGoogle Scholar
• Peterson LR. A review of tigecycline–the first glycylcycline. Int J Antimicrob Agents. 2008;32(Suppl 4):S215–S222. doi:10.1016/S0924-8579(09)70005-619134522
   PubMed Web of Science ®Google Scholar
• Wenzel R, Bate G, Kirkpatrick P. Tigecycline. Nat Rev Drug Discov. 2005;4(10):809–810. doi:10.1038/nrd185716237846
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162–1172. doi:10.1128/AAC.01402-1021173186
   PubMed Web of Science ®Google Scholar
• Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–1064. doi:10.1007/s00277-010-0911-720174923
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650–1655. doi:10.1128/AAC.04305-1425547356
   PubMed Web of Science ®Google Scholar
• Hu J, Xiao YH, Zheng Y, Lai YX, Fang XL, Fang Q. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):913–922. doi:10.1007/s00228-020-02860-w32355990
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Liu H, Ma W, Zhou S, Zhou J. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45(6):1434–1441. doi:10.1111/jcpt.1325032860258
   PubMed Web of Science ®Google Scholar
• Liu J, Yan Y, Zhang F. Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325–332. doi:10.2147/TCRM.S30285033888987
   PubMed Web of Science ®Google Scholar
• Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P, et al. Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm. 2020;42(4):1184–1189. doi:10.1007/s11096-020-01072-732504166
   PubMed Web of Science ®Google Scholar
• Hakeam HA, Al Duhailib Z, Salahuddin N, Amin T. Impact of tigecycline versus imipenem-cilastatin on fibrinogen levels following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a randomized-controlled study. J Chemother. 2018;30(4):224–232. doi:10.1080/1120009X.2018.145233329565228
   PubMed Web of Science ®Google Scholar
• Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–57. doi:10.1016/j.idcr.2018.01.00329560313
   PubMed Web of Science ®Google Scholar
• Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 2003;96(10):711–729. doi:10.1093/qjmed/hcg12914500858
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694. doi:10.1111/j.1538-7836.2005.01204.x15842354
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–2126. doi:10.1111/jth.1314026764429
   PubMed Web of Science ®Google Scholar
• Fan Q, Huang W, Weng Y, Xie X, Shi Z. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine. 2020;99(43):e22638. doi:10.1097/MD.000000000002263833120753
   PubMed Web of Science ®Google Scholar
• Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol. 1992;29(3):177–188.1641664
   PubMedGoogle Scholar
• Brandtner A, Bachler M, Fries D, et al. Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system. Antibiotics. 2020;9(2). doi:10.3390/antibiotics9020084.
   Web of Science ®Google Scholar
• Saliba R, Paasch L, El Solh A. Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol. 2009;31(4):583–588. doi:10.3109/0892397090283867219874226
   PubMed Web of Science ®Google Scholar
• Yang L, Vuylsteke A, Gerrard C, Besser M, Baglin T. Postoperative fibrinogen level is associated with postoperative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain. J Thromb Haemost. 2013;11(8):1519–1526. doi:10.1111/jth.1230423710825
   PubMed Web of Science ®Google Scholar